- Home
- PHAR vs MYGN Comparison
PHAR vs MYGN Comparison
Compare PHAR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- MYGN
- Stock Information
- Founded
- PHAR 1988
- MYGN 1991
- Country
- PHAR Netherlands
- MYGN United States
- Employees
- PHAR N/A
- MYGN N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PHAR Health Care
- MYGN Health Care
- Exchange
- PHAR Nasdaq
- MYGN Nasdaq
- Market Cap
- PHAR 731.1M
- MYGN 744.7M
- IPO Year
- PHAR N/A
- MYGN 1995
- Fundamental
- Price
- PHAR $10.00
- MYGN $5.34
- Analyst Decision
- PHAR Strong Buy
- MYGN Hold
- Analyst Count
- PHAR 3
- MYGN 15
- Target Price
- PHAR $30.00
- MYGN $15.14
- AVG Volume (30 Days)
- PHAR 3.6K
- MYGN 1.4M
- Earning Date
- PHAR 07-31-2025
- MYGN 08-05-2025
- Dividend Yield
- PHAR N/A
- MYGN N/A
- EPS Growth
- PHAR N/A
- MYGN N/A
- EPS
- PHAR N/A
- MYGN N/A
- Revenue
- PHAR $320,708,000.00
- MYGN $831,300,000.00
- Revenue This Year
- PHAR $13.31
- MYGN N/A
- Revenue Next Year
- PHAR $7.68
- MYGN $6.68
- P/E Ratio
- PHAR N/A
- MYGN N/A
- Revenue Growth
- PHAR 24.13
- MYGN 7.38
- 52 Week Low
- PHAR $6.65
- MYGN $3.81
- 52 Week High
- PHAR $12.61
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- MYGN 50.85
- Support Level
- PHAR $9.99
- MYGN $4.90
- Resistance Level
- PHAR $10.59
- MYGN $5.83
- Average True Range (ATR)
- PHAR 0.35
- MYGN 0.28
- MACD
- PHAR -0.14
- MYGN 0.04
- Stochastic Oscillator
- PHAR 7.45
- MYGN 54.21
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.